[6-K] Haleon plc Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc announced the purchase of 5,150,000 ordinary shares of £0.01 each on 23 September 2025 as part of the second tranche of its share buyback programme. The company intends to hold the purchased shares as treasury shares.

After settlement, registered share capital is 8,952,353,648 ordinary shares, of which 33,337,545 are treasury shares, leaving 8,919,016,103 ordinary shares with voting rights. The announcement includes a link to a full breakdown of individual trades and clarifies it is not an offer for securities.

Positive

• Executed buyback of 5,150,000 shares under the announced programme, demonstrating active capital return measures

Negative

• None.

Insights

Financial Analyst

TL;DR Share buyback executed; size is small relative to total shares, suggesting limited immediate EPS or voting impact.

The Company executed a tranche purchase of 5,150,000 shares and will hold them as treasury stock. Relative to registered share capital of 8,952,353,648 shares, this tranche represents roughly 0.06% of issued capital, indicating a modest capital reduction in this tranche. The action signals continued use of the announced buyback program but, given the tranche size versus outstanding shares, the near-term financial impact on per-share metrics is likely limited. Disclosure of individual trade details follows Market Abuse Regulation requirements.

Corporate Governance Expert

TL;DR Treasury purchase aligns with announced buyback and maintains shareholder notification transparency.

Haleon confirmed purchased shares will be held as treasury shares and provided voting-rights headcount for regulatory transparency. The firm supplied a link to a full trade breakdown, meeting disclosure obligations. Holding shares in treasury can provide flexibility for future capital management or employee compensation plans without immediately cancelling issued capital. No governance changes or executive actions are disclosed in this filing.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	24 September 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

24 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 5,150,000 ordinary shares of £0.01 each in the Company (the "Shares") under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	23 September 2025	23 September 2025	23 September 2025
Number of Shares purchased:	3,950,000	1,200,000	-
Highest price paid per Share (p):	333.3000	333.3000	-
Lowest price paid per Share (p):	329.8000	330.0000	-
Volume weighted average price paid per Share (p):	331.6889	331.6687	-

The Company intends to hold the purchased shares as treasury shares.

Following the settlement of the above, the Company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 33,337,545 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,919,016,103 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/5197A_1-2025-9-23.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 24, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

What did Haleon (HLNCF) announce in the 6-K filing?

Haleon announced the purchase of 5,150,000 ordinary shares on 23 September 2025 under the second tranche of its share buyback programme.

How many shares will Haleon hold as treasury after this transaction?

Following settlement, Haleon will hold 33,337,545 shares as treasury shares.

What is the number of ordinary shares with voting rights after the purchase?

The filing states there are 8,919,016,103 ordinary shares with voting rights after settlement.

Where can I find the full breakdown of individual trades for the buyback?

A full breakdown is available at the provided London Stock Exchange PDF link: http://www.rns-pdf.londonstockexchange.com/rns/5197A_1-2025-9-23.pdf and on Haleon's investor website.

Does this announcement constitute an offer for securities?

No. The filing explicitly states the announcement does not constitute an offer or solicitation for securities in any jurisdiction.